Literature DB >> 23099472

The crucial roles of IFN-γ in the development of M3 muscarinic acetylcholine receptor induced Sjögren's syndrome-like sialadenitis.

Mana Iizuka, Hiroto Tsuboi, Naomi Matsuo, Yuya Kondo, Hiromitsu Asashima, Minoru Matsui, Isao Matsumoto, Takayuki Sumida.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23099472     DOI： 10.1007/s10165-012-0785-8

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN： 1439-7595            Impact factor:   3.023


× No keyword cloud information.
  5 in total

1.  M3 muscarinic acetylcholine receptor-reactive Th17 cells in primary Sjögren's syndrome.

Authors:  Saori Abe; Hiroto Tsuboi; Hanae Kudo; Hiromitsu Asashima; Yuko Ono; Fumika Honda; Hiroyuki Takahashi; Mizuki Yagishita; Shinya Hagiwara; Yuya Kondo; Isao Matsumoto; Takayuki Sumida
Journal:  JCI Insight       Date:  2020-08-06

2.  RORγt antagonist suppresses M3 muscarinic acetylcholine receptor-induced Sjögren's syndrome-like sialadenitis.

Authors:  M Tahara; H Tsuboi; S Segawa; H Asashima; M Iizuka-Koga; T Hirota; H Takahashi; Y Kondo; M Matsui; I Matsumoto; T Sumida
Journal:  Clin Exp Immunol       Date:  2016-10-11       Impact factor: 4.330

3.  Blocking IAg7 class II major histocompatibility complex by drug-like small molecules alleviated Sjögren's syndrome in NOD mice.

Authors:  Shivai Gupta; Danmeng Li; David A Ostrov; Cuong Q Nguyen
Journal:  Life Sci       Date:  2021-11-27       Impact factor: 5.037

Review 4.  Contributions of Major Cell Populations to Sjögren's Syndrome.

Authors:  Richard Witas; Shivai Gupta; Cuong Q Nguyen
Journal:  J Clin Med       Date:  2020-09-22       Impact factor: 4.241

5.  Functional Analysis of Dendritic Cells Generated from T-iPSCs from CD4+ T Cell Clones of Sjögren's Syndrome.

Authors:  Mana Iizuka-Koga; Hiromitsu Asashima; Miki Ando; Chen-Yi Lai; Shinji Mochizuki; Mahito Nakanishi; Toshinobu Nishimura; Hiroto Tsuboi; Tomoya Hirota; Hiroyuki Takahashi; Isao Matsumoto; Makoto Otsu; Takayuki Sumida
Journal:  Stem Cell Reports       Date:  2017-05-09       Impact factor: 7.765
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.